Search Result

Results for "

FAAH Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FAAH (90) 5-HT Receptor (2) Apoptosis (1) Autophagy (30) Bacterial (2) Cannabinoid Receptor (5) Ceramidase (3) Cholinesterase (ChE) (1) COX (5) DAGL (1) Endogenous Metabolite (10) Environmental Pollutants (1) Epoxide Hydrolase (2) Fungal (2) Glutathione Peroxidase (2) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (1) MAGL (20) Mitophagy (2) NEDD8-activating Enzyme (1) Nucleoside Antimetabolite/Analog (2) Phospholipase (1) Potassium Channel (1) PPAR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (12) SARS-CoV (3) TRP Channel (2) Tyrosine Hydroxylase (1) Virus Protease (2)
By Research Areas:	Cancer (13) Cardiovascular Disease (4) Infection (8) Inflammation/Immunology (22) Metabolic Disease (21) Neurological Disease (60)

By Targets:

FAAH (90)

5-HT Receptor (2)

Apoptosis (1)

Autophagy (30)

Bacterial (2)

Cannabinoid Receptor (5)

Ceramidase (3)

Cholinesterase (ChE) (1)

COX (5)

DAGL (1)

Endogenous Metabolite (10)

Environmental Pollutants (1)

Epoxide Hydrolase (2)

Fungal (2)

Glutathione Peroxidase (2)

Influenza Virus (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

MAGL (20)

Mitophagy (2)

NEDD8-activating Enzyme (1)

Nucleoside Antimetabolite/Analog (2)

Phospholipase (1)

Potassium Channel (1)

PPAR (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (12)

SARS-CoV (3)

TRP Channel (2)

Tyrosine Hydroxylase (1)

Virus Protease (2)

By Research Areas:

Cancer (13)

Cardiovascular Disease (4)

Infection (8)

Inflammation/Immunology (22)

Metabolic Disease (21)

Neurological Disease (60)

100

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: FAAH

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14595

Biochanin A Maximum Cited Publications 15 Publications Verification 4-Methylgenistein; Olmelin	FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-B0182

Carmofur 5+ Cited Publications HCFU	Nucleoside Antimetabolite/Analog SARS-CoV Virus Protease FAAH Ceramidase Glutathione Peroxidase	Infection Inflammation/Immunology Cancer
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .

HY-15249

JZL 184 5+ Cited Publications	MAGL	Neurological Disease
JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC₅₀ of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .

HY-B1227

Carprofen 5+ Cited Publications	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target *FAAH/COX* inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-10864

URB-597 5 Publications Verification KDS-4103	FAAH Autophagy Mitophagy	Neurological Disease
URB-597 (KDS-4103) is an orally bioavailable and selective *FAAH* inhibitor. URB-597 inhibits FAAH activity with an IC₅₀s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .

HY-14380

PF-3845 2 Publications Verification	FAAH Autophagy	Inflammation/Immunology Cancer
PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a K_i of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .

HY-14376

Redafamdastat 5+ Cited Publications PF-04457845	FAAH Autophagy	Neurological Disease
Redafamdastat (PF-04457845), a chemical probe, is a highly efficacious and selective *FAAH* inhibitor with IC₅₀ values is 7.2±0.63 nM and 7.4±0.62 nM for hFAAH and rFAAH, respectively.

HY-119283

CAY10499 1 Publications Verification MAGL-IN-5	MAGL FAAH SARS-CoV Influenza Virus	Infection Metabolic Disease Inflammation/Immunology
CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC₅₀ values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities .

HY-116477

URB937	FAAH	Neurological Disease Inflammation/Immunology
URB937 is an orally active and peripherally restricted *FAAH* inhibitor (IC₅₀=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier) .

HY-15250

JZL195 4 Publications Verification	FAAH MAGL Autophagy	Neurological Disease
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 2 and 4 nM, respectively .

HY-10862

FAAH inhibitor 1 Benzothiazole analog 3	FAAH Autophagy	Neurological Disease Cancer
FAAH inhibitor 1 (compound 3) is a selective reversible *FAAH* inhibitor. FAAH inhibitor 1 has no off-target activity with respect to other serine hydrolases. FAAH inhibitor 1 is exclusively specific against FAAH in rat brain with an IC₅₀ value of 18 nM and had no missing protein bands in all the other tissues. FAAH inhibitor 1 can be used for neurological disorders research .

HY-18540

KT109 1 Publications Verification	MAGL DAGL	Metabolic Disease Inflammation/Immunology
KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC₅₀ of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC₅₀=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-Arachidonoylglycerol (HY-W011051), Arachidonic acid (HY-109590) and eicosanoids in mouse peritoneal macrophages .

HY-N2365

Macamide B 2 Publications Verification N-Benzylpalmitamide; N-Benzylhexadecanamide; Macamide 1	FAAH Autophagy	Others
Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-19740

BIA 10-2474 2 Publications Verification	FAAH Autophagy	Neurological Disease
BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC₅₀ values of 50 to 70mg/kg in various rat brain regions.

HY-10865

LY2183240 3 Publications Verification	FAAH Autophagy	Neurological Disease
LY2183240 is a highly potent blocker of anandamide uptake (IC₅₀= 270 pM; K_i=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase *(FAAH)* with an IC₅₀ of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC₅₀s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .

HY-18977

KML29 3 Publications Verification	MAGL	Metabolic Disease Inflammation/Immunology
KML29 is an extremely selective, orally active and irreversible MAGL inhibitor, with IC₅₀ values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH .

HY-N7062

JNJ-1661010 Takeda-25	FAAH	Neurological Disease
JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics .

HY-18081

PF 750	FAAH Autophagy	Neurological Disease Metabolic Disease
PF 750 is a selective, covalent and brain-penetrant fatty acid amide hydrolase (FAAH) inhibitor. PF 750 covalently carbamylates FAAH's catalytic serine nucleophile to inactivate the enzyme .

HY-77491

FAAH/MAGL-IN-5	FAAH MAGL	Neurological Disease
AM6701 is a potent *FAAH/MAGL* inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects .

HY-120961

Oleoyl ethyl amide N-Ethyloleamide	FAAH	Metabolic Disease
Oleoyl ethyl amide (N-Ethyloleamide) is a fatty acid amide hydrolase (FAAH) inhibitor. Oleoyl ethyl amide can counteract bladder overactivity .

HY-125967

AM 374	FAAH	Neurological Disease
AM 374 is an fatty acid amide hydrolase *(FAAH)* inhibitor. AM 374 inhibits amidase activity with an IC₅₀ value of 13 nM. AM 374 can be used for the research of neurological disease .

HY-19636

JNJ-42165279	FAAH Autophagy	Neurological Disease
JNJ-42165279 is an orally active *FAAH* inhibitor, with IC₅₀ values of 70 nM for hFAAH and 313 nM for rFAAH. JNJ-42165279 can be used in research related to the field of neuropathic pain .

HY-101457

JZP-430	MAGL	Metabolic Disease
JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC₅₀ of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .

HY-131678

Palmitoyl serotonin PA-5HT	FAAH	Neurological Disease
Palmitoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin, antagonist of FAAH. Palmitoyl serotonin inhibits L-3,4-dihydroxyphenylalanine (HY-N0304) induced abnormal involuntary movements. Palmitoyl serotonin has the potential for the research of parkinson's disease (PD) .

HY-N2512

1-Monomyristin 1 Publications Verification	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal	Infection Cancer
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat *FAAH* and an IC₅₀ of 32 μM against rat MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

HY-79511

FAAH-IN-2 1 Publications Verification O-Desmorpholinopropyl Gefitinib	FAAH Autophagy	Others
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is an inhibitor of *FAAH. FAAH-IN-2 is a metabolite of Gefitinib (HY-50895)* .

HY-177093

Irafamdastat BMS-986368; CC-97489; ABX-1772	MAGL FAAH	Neurological Disease
Irafamdastat (BMS-986368) (Example 74) is a *FAAH* and MAGL inhibitor, with IC₅₀s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect .

HY-155773

VU534	FAAH Epoxide Hydrolase	Cardiovascular Disease
VU534 is a NAPE-PLD activator, with an EC₅₀ of 0.30 μM. VU534 is dual inhibitors of *FAAH* and sEH (IC₅₀ of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study ^[1].

HY-118158

FAAH/MAGL-IN-4	FAAH	Neurological Disease
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .

HY-103462

TC-F2	FAAH	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .

HY-N2428

N-(3-Methoxybenzyl)Palmitamide	FAAH	Neurological Disease
N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of *FAAH* for the treatment of pain, inflammation and CNS degenerative disorders .

HY-18544

AA38-3	MAGL FAAH	Metabolic Disease
AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .

HY-15249R

JZL 184 (Standard)	MAGL Reference Standards	Neurological Disease
JZL 184 (Standard) is the analytical standard of JZL 184. This product is intended for research and analytical applications. JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .

HY-14595R

Biochanin A (Standard) Maximum Cited Publications 15 Publications Verification 4-Methylgenistein(Standard); Olmelin (Standard)	Reference Standards FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-163733

AKU-005	FAAH MAGL	Neurological Disease Inflammation/Immunology
AKU-005 is a *FAAH* and MAGL dual inhibitor with IC₅₀ values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia .

HY-152254

CB2R/FAAH modulator-3	FAAH Cannabinoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and *FAAH* inhibitor. The K_i values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .

HY-152251

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

HY-B1227R

Carprofen (Standard)	Reference Standards COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-123863

SSR411298	FAAH	Neurological Disease
SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research .

HY-103337

N-Arachidonoylserotonin Arachidonyl serotonin; AA-5-HT	FAAH TRP Channel	Neurological Disease
N-Arachidonoylserotonin (Arachidonyl serotonin; AA-5-HT) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ value of 1~12 µM. N-Arachidonoylserotonin acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels (IC₅₀=70~100 nM). N-Arachidonoylserotonin is analgesic in rodents .

HY-111389

FAAH-IN-1	FAAH Autophagy	Metabolic Disease
FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC₅₀s of 145 nM and 650 nM for rat and human FAAH, respectively.

HY-118210

PHOP	FAAH	Metabolic Disease
PHOP is a fatty acid amide hydrolase (FAAH) inhibitor used to assess inhibitory activity in a fluorometric assay. PHOP can determine FAAH activity by measuring the amount of 4-pyridin-1-ylbutyric acid released by the enzyme in rat brain microsomes. PHOP demonstrates potential as a FAAH inhibitor and can directly measure FAAH activity by reversed-phase HPLC and fluorescence detection, providing a basis for the development of new inhibitors.

HY-175816

5-HT6R/FAAH modulator 1	5-HT Receptor FAAH Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
5-HT6R/FAAH modulator 1 is a selective serotonin 5-HT6 receptor ligand and the fatty acid amide hydrolase (FAAH) enzyme inhibitor. 5-HT6R/FAAH modulator 1 shows a pK_i of 6.33 (5-HT6) and a pIC₅₀ valuesof 6.29 (FAAH). 5-HT6R/FAAH modulator 1 also slightly inhibits acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) enzymes (pIC₅₀ = 5.12). 5-HT6R/FAAH modulator 1 can inhibit apoptosis and reduce ROS levels. 5-HT6R/FAAH modulator 1 can be used for the research of neurological disease, such as Alzheimer’s disease (AD) .

HY-116798

URB524	FAAH	Neurological Disease
URB524 is an irreversible *FAAH* inhibitor of O-aryl amino acid esters. URB524 inhibits FAAH by aminoformylation of Ser241. URB524 exhibits analgesic, antidepressant, and anti anxiety activity .

HY-144738

Dual FAAH/sEH-IN-1	Epoxide Hydrolase FAAH	Inflammation/Immunology
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and *FAAH* (fatty acid amide hydrolase) inhibitor, with IC₅₀ values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .

HY-103461

FAAH-IN-6	FAAH	Neurological Disease
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain .

HY-18080

SA 47	FAAH Autophagy	Metabolic Disease
SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate .

HY-B1227S

Carprofen-d3	COX FAAH Autophagy Endogenous Metabolite	Inflammation/Immunology
Carprofen-d₃ is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N3033

N-Benzyllinolenamide 1 Publications Verification	FAAH Autophagy	Metabolic Disease
N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 41.8 μM .

HY-139384

FAAH inhibitor 2	FAAH	Neurological Disease
FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC₅₀ of 0.153 μM .

Cat. No.	Product Name

HY-L013

Neuronal Signaling Compound Library

3,802 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 3,802 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14595

Biochanin A Maximum Cited Publications 15 Publications Verification 4-Methylgenistein; Olmelin	Neurological Disease Classification of Application Fields Trifolium pratense Linn. Plants Flavonoids Leguminosae Sunscreen Phenols Polyphenols Cosmetic Research Disease Research Fields Isoflavones Source Classification Cancer	FAAH Autophagy Endogenous Metabolite
Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-B1227

Carprofen 5+ Cited Publications	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	COX FAAH Autophagy Endogenous Metabolite
Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target *FAAH/COX* inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N2365

Macamide B 2 Publications Verification N-Benzylpalmitamide; N-Benzylhexadecanamide; Macamide 1	Alkaloids other families Classification of Application Fields Other Alkaloids Other Diseases Plants Disease Research Fields Source Classification	FAAH Autophagy
Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-N2512

1-Monomyristin 1 Publications Verification	Infection Structural Classification Serenoa repens Classification of Application Fields Palmae Plants Disease Research Fields Steroids	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat *FAAH* and an IC₅₀ of 32 μM against rat MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

HY-N2428

N-(3-Methoxybenzyl)Palmitamide	Natural Products other families Plants Source Classification	FAAH
N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of *FAAH* for the treatment of pain, inflammation and CNS degenerative disorders .

HY-14595R

Biochanin A (Standard) Maximum Cited Publications 15 Publications Verification 4-Methylgenistein(Standard); Olmelin (Standard)	Flavonoids Neurological Disease Classification of Application Fields Leguminosae Sunscreen Phenols Cosmetic Research Trifolium pratense Linn. Plants Disease Research Fields Source Classification Cancer	Reference Standards FAAH Autophagy Endogenous Metabolite
Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-B1227R

Carprofen (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards COX FAAH Autophagy Endogenous Metabolite
Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-N3033

N-Benzyllinolenamide 1 Publications Verification	Alkaloids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Source Classification	FAAH Autophagy
N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 41.8 μM .

HY-N2365R

Macamide B (Standard) N-Benzylpalmitamide (Standard); N-Benzylhexadecanamide (Standard); Macamide 1 (Standard)	Alkaloids Structural Classification other families Other Alkaloids Plants Source Classification	Reference Standards FAAH Autophagy
Macamide B (Standard) is the analytical standard of Macamide B. This product is intended for research and analytical applications. Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-N2512R

1-Monomyristin (Standard)	Structural Classification Serenoa repens Palmae Plants Steroids	Reference Standards FAAH Bacterial Fungal Endogenous Metabolite Autophagy
1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans .

Cat. No.	Product Name	Chemical Structure

HY-B1227S

Carprofen-d3
Carprofen-d₃ is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

HY-B1227S1

Carprofen-13C,d3
Carprofen- ¹³C,d₃ is the deuterium and ¹³C labeled Carprofen . Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC₅₀s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively .

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks